fashion -WSS

fashion

author：explore 2025-09-28 21:05:54 - browse：52

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： AstraZeneca stays mum on Medicare drug pricing negotiations

focus

WSS

FTX founder Sam Bankman

Judge rejects Trump's counterclaim against E. Jean Carroll

Updated Covid vaccine has 54% effectiveness, new study suggests

Surgery pushed Ben Carson to fame

Former Georgia lieutenant governor says he received grand jury subpoena

Padmanee Sharma of MD Anderson at center of lawsuit over credit

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Heart attack and stroke risk calculators need revising

Cheesesteak restaurant owner explains his secret sauce, the viral Malibu Barbie Dream Drizzle

Apple is now the first public company to be valued at $3 trillion

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Cancer drug shortages should be causing more outrage

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Jerome Adams on the need for new antivirals for Covid

340B reform proposal comes out of Senate working group

focus

Sage's campaign to raise awareness of postpartum depression hits a nerve

Wegovy cuts risk of cardiovascular events by 20%, study finds

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Bernie brings in new pharma CEOs to talk drug prices

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

340B reform proposal comes out of Senate working group

entertainment

focus

hotspot

entertainment